Henlius' Herceptin Biosimilar Approved for European Use
publication date: Jul 30, 2020
Shanghai Henlius Biotech has been approved to market its Herceptin biosimilar to patients with HER2-positive cancers in Europe. Zercepac® is the first Henlius biosimilar to be approved for use in Europe. One year ago, the company was approved to market its Rituxan biosimilar in China to treat non-Hodgkin lymphoma, the first biosimilar approved in China. Henlius, a subsidiary of Fosun Pharma, partnered the biosimilar with Accord Pharma of the UK for European distribution. It is Accord's third approved biosimilar. More details....
Stock Symbols: (HK: 2696) (SHA: 600196; HK: 2196)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.